# Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

> **NCT03012672** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 50 (actual)

## Conditions studied

- Acute Leukemia of Ambiguous Lineage
- Acute Myeloid Leukemia
- Myeloid Neoplasm

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **BIOLOGICAL:** Granulocyte Colony-Stimulating Factor
- **DRUG:** Mitoxantrone Hydrochloride
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03012672
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-30
- **Primary completion:** 2020-12-10
- **Final completion:** 2021-02-26
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03012672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03012672, "Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03012672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*